Breaking news on Acid Reflux and GORD
Data Suggests Proton Pump Inhibitors Can Induce Acid-Related Symptoms In Healthy Adults published
Fri, 03 Jul 2009 01:00:00 PDT
Treatment with proton pump inhibitors (PPIs) for eight weeks induces acid-related symptoms like heartburn, acid regurgitation and dyspepsia once treatment is withdrawn in healthy individuals, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.
What Is Different In Reflux Esophagitis Between African-Americans And Non-Hispanic Whites? published
Fri, 26 Jun 2009 00:00:00 PDT
There is minimal data evaluating the prevalence of GERD complications in any United States general population, other than non-Hispanic whites. Presently, it is thought that such complications occur less frequently in African-Americans than in non-Hispanic whites. A research group in Jacksonville, FL investigated the prevalence of reflux esophagitis between non-Hispanic whites and African-Americans.
Anti Nausea Drug Deemed Safe For Fetuses: Ben-Gurion U. published
Fri, 12 Jun 2009 01:00:00 PDT
Metoclopramide, a drug approved in the U.S. for nausea, vomiting and heartburn poses no significant risks for the fetus according to a large cohort study published in the June 11 issue of the prestigious New England Journal of Medicine, "The Safety of Metoclopramide Use in the First Trimester of Pregnancy" (N Engl J Med 2009;360:24 June 11, 2009). According to the pediatrician and clinical pharmacologist, principal investigator Dr. Rafael Gorodischer, prof.
Shedding Light On Esophageal Disease published
Tue, 09 Jun 2009 06:00:00 PDT
Canadian Light Source (CLS) staff scientist Luca Quaroni and Dr. Alan Casson, Head of the Department of Surgery at the University of Saskatchewan (U of S) used the synchrotron's infrared microscope to identify tissue afflicted with a condition known as Barrett's Esophagus from chemical fingerprints associated with the disease, which can lead to esophageal cancer. The finding is published in the June, 2009 issue of the Royal Society of Chemistry journal, The Analyst.
Additional Phase II Data Demonstrate Improvement In Reported Symptoms In Patients Who Still Experience GERD Symptoms Despite PPI Therapy published
Fri, 05 Jun 2009 05:00:00 PDT
Adding AZD3355, a novel GABAB receptor agonist, to a proton pump inhibitor (PPI) in patients with Gastroesophageal Reflux Disease (GERD), resulted in a 35% reduction in the mean total number of reflux episodes 0-24 hours after dose, compared with placebo.[i] These data were presented at the Digestive Diseases Week annual meeting (DDW®, 30 May - 4 June, Chicago).
Barrett's Esophagus Can Be Reversed And Cancer Risk Reduced By Radiofrequency Ablation NEJM Study Finds published
Thu, 04 Jun 2009 01:00:00 PDT
Patients who have gastroesophageal reflux disease (GERD) for a prolonged period have an increased risk of developing Barrett's esophagus, a pre-cancerous condition where the tissue lining the esophagus becomes damaged by stomach acid and transformed into something like the inside of the stomach. New research finds that radiofrequency ablation -- an endoscopic procedure involving targeted thermal energy -- was very successful at restoring the esophagus and reducing risk for cancer.
Identification Of Potential Risks Of Therapies Taken By The Elderly published
Wed, 03 Jun 2009 06:00:00 PDT
Researchers unveiled data during Digestive Disease Week® (DDW®) 2009 examining the potential risks associated with two commonly-used treatments, particularly among the elderly: acid suppressors and antithrombotics. DDW is the largest international gathering of physicians and researchers in the field of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.
AstraZeneca Studies Show Relief Of Nighttime Heartburn And Reduction In GERD-Related Sleep Disturbances published
Wed, 03 Jun 2009 01:00:00 PDT
Two studies from AstraZeneca (NYSE: AZN) show that symptomatic gastroesophageal reflux disease (GERD) patients treated with NEXIUM(R) (esomeprazole magnesium) 20 mg daily experienced greater relief from nighttime heartburn and GERD-related sleep disturbances compared with patients taking placebo over four weeks(1). NEXIUM 20 mg is indicated for the treatment of heartburn and other symptoms associated with GERD.
Technique Eradicates Problems In Most Patients With Barrett's Esophagus published
Fri, 29 May 2009 00:00:00 PDT
A procedure that uses heat generated by radio waves to treat Barrett's esophagus, a condition caused by acid reflux (severe heartburn), can eliminate signs of the potentially cancer-causing disorder and reduce the risk that the disease will progress. Findings from the first multicenter trial of the procedure, called radiofrequency ablation, could mean patients have an alternative to surgery for treating Barrett's esophagus.
No Change In Pharmacokinetics Of ADHD Medication VYVANSE CII When Coadministered With Prilosec published
Mon, 25 May 2009 00:00:00 PDT
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication VYVANSE® (lisdexamfetamine dimesylate) CII with the proton pump inhibitor (PPI) Prilosec OTC® 40 mg (20 mg X 2), did not alter the median time it took for maximum plasma concentration of d-amphetamine to be reached in the subjects evaluated.
Lansoprazole Can Cause Chronic Diarrhea Unresponsive To Conventional Medication published
Thu, 14 May 2009 06:00:00 PDT
Lansoprazole is a proton pump inhibitor which powerfully suppresses gastric acid production and is widely prescribed for chronic use in gastroesophageal reflux disease. Lansoprazole uncommonly causes chronic watery diarrhea unresponsive to conventional medication as a symptom of collagenous colitis. This association has recently been reported and is not widely known. Correct diagnosis and treatment without this knowledge is impossible.
Benefits Of Anti-Clotting Medications Reduced By Common Heartburn Drugs published
Thu, 07 May 2009 05:00:00 PDT
The anti-clotting action of the medication clopidogrel (Plavix) can be compromised by common drugs for the treatment of heartburn and ulcers resulting in a roughly 50% increase in the combined risk of hospitalization for heart attack, stroke and other serious cardiovascular illnesses, according to a new study presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 32nd Annual Scientific Sessions.
Angina And Gastroesophageal Reflux Diseases Linked published
Mon, 20 Apr 2009 01:00:00 PDT
It is well known that non-cardiac chest pain is closely related to gastroesophageal reflux diseases (GERD). Chest pain of esophageal origin can be difficult to distinguish from that caused by cardiac ischemia because the distal esophagus and the heart share a common afferent vagal supply, and GERD can cause episodes of non-cardiac chest pain that resemble ischemic cardiac pain. A research team led by Dr.
What Is Acid Reflux? What Causes Acid Reflux? published
Sun, 19 Apr 2009 04:00:00 PDT
The word "reflux" comes from the Medieval Latin word refluxus which comes from the Latin word refluere, meaning "to flow back, to recede". If you suffer from acid reflux the acids from your stomach "flow back" into your esophagus, causing discomfort and pain - this discomfort is known as heartburn.
Study Of Biodegradable Gel As A Treatment For Esophageal Cancer published
Thu, 16 Apr 2009 06:00:00 PDT
Gastroenterologists at Rush University Medical Center are studying the safety and efficacy of a new system for delivering chemotherapy for patients with esophageal cancer, a rare, but deadly disease that attacks the throat. The unique drug therapy delivers a highly concentrated dose of chemotherapy injected directly on to the hard-to-reach tumors in the esophagus non-surgically. Researchers at Rush are trying to determine if the gel treatment can reduce the size of the cancerous tumors.
Santarus Announces FDA Acceptance Of New Drug Application For ZEGERID Tablet Product published
Tue, 07 Apr 2009 00:00:00 PDT
Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company's New Drug Application (NDA) for a new tablet formulation to add to its ZEGERID® family of branded prescription pharmaceutical products. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, Santarus expects the FDA will complete its review or otherwise respond to the NDA by December 4, 2009.
Acid Reflux Treatment Has No Impact On Asthma published
Mon, 06 Apr 2009 04:00:00 PDT
Having to deal with asthma is bad enough, but to make matters worse, one out of every three asthmatics in this country also suffers from acid reflux.* For years doctors thought that treating acid reflux might be able to help with asthma. But a new study in the April 9th issue of the New England Journal of Medicine casts some doubts about that.
Torax Medical Launches Pivotal Clinical Study Of New Acid Reflux Treatment published
Sat, 04 Apr 2009 00:00:00 PDT
Torax Medical Inc., a medical device company focused on the minimally invasive treatment of gastroesophageal reflux disease (GERD) has commenced a pivotal clinical trial of its LINX(TM) Reflux Management System. The trial, which is being conducted at 15 leading academic and private medical centers in the U.S. and Europe, will evaluate the safety and effectiveness of the LINX System in patients suffering from GERD despite medical therapy.
Heart Burn Surgery Reverses Chronic Rejection In Transplant Patient published
Wed, 01 Apr 2009 04:00:00 PDT
Acid reflux is thought to be at most an irritating condition easily controlled with medication, diet and weight loss. Mary Prucha thought so too. But that was before she woke up struggling for air one night last September, nearly two years after undergoing a rare double-lung re-transplant.
Further Research Urged By Barrett's Oesophagus Campaign published
Thu, 05 Mar 2009 06:00:00 PDT
In response to media reports that a glass of wine 'cuts risk of gullet cancer'taken from two authoritative studies reported in the magazine Gastroenterology 136, issue 3 March 2009: The newly launched Barrett's Oesophagus Campaign - the only charity dedicated to the prevention
Is Esomeprazole The Best Choice For Reflux Esophagitis Patients? published
Wed, 04 Mar 2009 03:00:00 PDT
In patients with gastroesophageal reflux disease (GERD), esomeprazole, has demonstrated pharmacological and clinical benefits beyond those seen with the other proton pump inhibitors( PPIs ). However it has not hitherto been fully determined whether differences in the onset of antisecreatary activity may affect the speed of symptom relief with different PPI. Dr. Ri-Nan Zheng from China addresses this question.
Risk Of Barrett's Esophagus May Be Lowered By 1 Glass Of Wine A Day published
Tue, 03 Mar 2009 05:00:00 PDT
Drinking one glass of wine a day may lower the risk of Barrett's Esophagus by 56 percent, according to a new study by the Kaiser Permanente Division of Research in the March issue of Gastroenterology. Barrett's Esophagus is a precursor to esophageal cancer, the nation's fastest growing cancer with an incidence rate that's jumped 500 percent in the last 30 years.
Alcohol Types And Socioeconomic Status Are Associated With Barrett's Esophagus Risk published
Mon, 02 Mar 2009 01:00:00 PDT
Additional study suggests drinking alcohol in early adulthood may increase reflux esophagitis risk Although the relationship between alcohol and esophageal squamous cell carcinoma is well established, studies investigating the association between alcohol intake and reflux esophagitis (RE), Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) have reported inconsistent findings.
New Incision-Free Procedure For Severe Acid Reflux published
Sat, 28 Feb 2009 01:00:00 PDT
A national leader in incision-free surgery performed through natural orifices, the Center for Scarless Surgery at NewYork-Presbyterian Hospital/Columbia University Medical Center is now offering patients with severe, chronic acid reflux disease a unique incision-free procedure called TIF, or transoral incisionless fundoplication.
Magnetic Device Studied As Treatment For Heartburn And Acid Reflux published
Tue, 24 Feb 2009 03:00:00 PDT
More than 20 million Americans suffer from gastroesophageal reflux disease (GERD), experienced by many as chronic heartburn. Medication offers short-term relief for some sufferers of this disease. For those seeking a non-prescription alternative, a magnetic device, currently being evaluated at UC San Diego Medical Center, may provide a long-term solution.
|
|
